Brokers Offer Predictions for MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Equities researchers at Diamond Equity issued their Q1 2026 EPS estimates for MAIA Biotechnology in a research note issued to investors on Tuesday, March 25th. Diamond Equity analyst H. Diamond anticipates that the company will post earnings of ($0.18) per share for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.69) EPS.

MAIA Biotechnology Price Performance

Shares of MAIA Biotechnology stock opened at $1.57 on Wednesday. The company has a market capitalization of $41.07 million, a PE ratio of -1.14 and a beta of 0.20. MAIA Biotechnology has a 1-year low of $1.46 and a 1-year high of $5.99. The business’s 50-day moving average price is $1.87.

Institutional Investors Weigh In On MAIA Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in MAIA Biotechnology in the third quarter valued at approximately $31,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the 4th quarter valued at about $77,000. Finally, Geode Capital Management LLC increased its position in shares of MAIA Biotechnology by 22.9% during the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after purchasing an additional 35,821 shares during the last quarter. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.